Back

XYone Therapeutics doses first patient in XYA02 Phase 1b/2 trial

Verifying
  • XYone Therapeutics dosed the first patient in its Phase 1b/2 XYA02 cancer trial.
  • The trial is registered as NCT07670312 and evaluates XYA02 in advanced solid tumors.
  • FDA granted XYA02 Orphan Drug Designation for pancreatic and gastric cancer.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.